Your browser doesn't support javascript.
loading
A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
Kumamoto, Tadashi; Aoki, Yuki; Sonoda, Tomoko; Yamanishi, Miho; Arakawa, Ayumu; Sugiyama, Masanaka; Shirakawa, Nami; Ishimaru, Sae; Saito, Yoshimasa; Maeshima, Akiko; Maeda, Miho; Ogawa, Chitose.
Afiliação
  • Kumamoto T; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan. tkumamot@ncc.go.jp.
  • Aoki Y; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan.
  • Sonoda T; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan.
  • Yamanishi M; Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
  • Arakawa A; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan.
  • Sugiyama M; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan.
  • Shirakawa N; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan.
  • Ishimaru S; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan.
  • Saito Y; Department of Pharmacy, National Cancer Center Hospital, Tokyo, Japan.
  • Maeshima A; Department of Pathology, National Cancer Hospital, Tokyo, Japan.
  • Maeda M; Department of Pediatrics, Nippon Medical School, Tokyo, Japan.
  • Ogawa C; Department of Pediatric Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ki, Tokyo, 104-0045, Japan.
Int J Hematol ; 109(2): 228-232, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30361829
ABSTRACT
Histiocytic sarcoma in advanced clinical stages is typically an aggressive neoplasm, with poor response to conventional chemotherapy. An 18-year-old male with refractory histiocytic sarcoma that had transformed from Rosai-Dorfman disease was admitted to our hospital. A pathogenic variant of MAP2K1 was detected by next-generation sequencing of tumor specimens. Affected regions showed excellent responses to the MEK inhibitor trametinib. It has been reported that RAS/MEK/ERK pathway is activated in many cases of histiocytic sarcoma. MEK inhibition may represent a useful treatment option in histiocytic sarcoma.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridonas / Pirimidinonas / MAP Quinase Quinase 1 / Sarcoma Histiocítico Limite: Adolescent / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Piridonas / Pirimidinonas / MAP Quinase Quinase 1 / Sarcoma Histiocítico Limite: Adolescent / Humans / Male Idioma: En Ano de publicação: 2019 Tipo de documento: Article